Early ALS drug trial halted: safety first in fight against nerve disease
NCT ID NCT06215755
Summary
This early-stage study aimed to test the safety and side effects of an experimental drug called VRG50635 in people with ALS (Lou Gehrig's disease). It involved 54 adults with ALS to see how their bodies handled increasing doses of the drug over time and to look for early signs it might help slow the disease. The trial was terminated, meaning it was stopped early, which is common in early-phase studies focused primarily on safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Helsinki University Hospital
Helsinki, Uusimaa, FI-00029, Finland
-
Stan Cassidy Centre for Rehabilitation (Horizon NB)
Montreal, Quebec, H3A 2B4, Canada
-
The Neuro - Montréal Neurological Institute-Hospital
Montreal, Quebec, H3A 2B4, Canada
-
Turku University Hospital
Turku, Western Finland, FI-20520, Finland
-
UZ Leuven
Leuven, Flemish Brabant, Belgium
-
University Medical Center Utrecht
Utrecht, 3584 CX, Netherlands
-
University of Eastern Finland, Brain Research Unit
Kuopio, Eastern Finland, FI-70210, Finland
Conditions
Explore the condition pages connected to this study.